Cyclophosphamide
T-Cell Dysfunction
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the T-Cell Dysfunction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Equine Atg | Phase 1/2 | CCC |
Fludarabine | Phase 1/2 | CCC |
Busulphan | Phase 1/2 | CCC |
cd3/cd19 negative allogeneic hematopoietic stem cells Paul Szabolcs | Phase 1/2 | CCC |
Docetaxel The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | D |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →